XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.
April 29, 2024
Share
XOMA Corporation (NasdaqGM:XOMA) acquired three First-in-Category Assets of Daré Bioscience, Inc. (NasdaqCM:DARE) for $22 million on April 30, 2024. As a part of consideration, XOMA is entitled to potential milestone payments based on the commercial success of XACIATO. Gibson, Dunn & Crutcher LLP acted as a legal advisor to XOMA Corporation and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C of Cowen Inc. acted as a financial advisor to Daré Bioscience, Inc.
XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. (NasdaqCM:DARE) on April 30, 2024.
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
DARÉ BIOSCIENCE, INC. 
